Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00505921
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
- Conditions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Phramongkutklao College of Medicine and Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00472433
- Locations
- 🇹🇭
Phramongkutklao Hospital, Bangkok, Thailand
Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2013-09-06
- Target Recruit Count
- 86
- Registration Number
- NCT00462332
- Locations
- 🇮🇹
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy
🇮🇹Ospedale Regionale A. Pugliese, Catanzaro, Italy
🇮🇹Universita di Ferrara, Ferrara, Italy
Alemtuzumab and Pentostatin In T-cell Neoplasms
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00453193
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2009-06-25
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 4
- Registration Number
- NCT00441025
- Locations
- 🇹🇭
Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00436904
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
- Conditions
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00416884
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
- Conditions
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 53
- Registration Number
- NCT00408447
- Locations
- 🇺🇸
Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, New York, New York, United States
HSCT for High Risk Inherited Inborn Errors
- Conditions
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 38
- Registration Number
- NCT00383448
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 82
- Registration Number
- NCT00337519
- Locations
- 🇩🇪
Uniklinikum Carl Gustav Carus, Dresden, Germany
🇩🇪Klinikum Chemnitz gGmbH, Chemnitz, Germany
🇩🇪Deutsche Klinik für Diagnostik GmbH, Wiesbaden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.